Immuron Limited
- IMRN
- NASDAQ
- Biotechnology
- Polyclonal Antibody Therapies
$0.96
Today −2.62%Quote Oct 19, 2026, 08:00 PM UTC
−21.61%over the last month
Max drawdown −23.8%From 1-month high −23.8%3 months −21.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Immuron
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
7
Market value
$308.8M
Quote Oct 19
Floor
$0.92
3.4% below price
Resistance
$1.01
5.8% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about IMRNPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free